Aprepitant
DefinitionThis section has been translated automatically.
Antiemetic, neurokinin-1 (NK1) antagonist.
Half-lifeThis section has been translated automatically.
9-13 hours
Pharmacodynamics (Effect)This section has been translated automatically.
Blockade of NK-1 receptors in the brain and enhancement of the antiemetic effect of 5-HT3 receptor antagonists as well as of dexamethasone in antiemetic combination therapies Aprepitant also has an antipruritic effect.
IndicationThis section has been translated automatically.
Prevention of acute and refractory nausea/vomiting in highly emetogenic cisplatin-based chemotherapy, as part of a combination therapy.
As an individual healing trial in therapy-resistant Prurigo nodularis.
Pregnancy/nursing periodThis section has been translated automatically.
Should not be used during pregnancy (insufficient data available). Contraindicated during lactation.
Dosage and method of useThis section has been translated automatically.
125 mg p.o. once/day on day 1. 80 mg p.o. each on day 2 and 3.
Undesirable effectsThis section has been translated automatically.
Occasionally/rarely: loss of appetite, weight gain. Rarely disorientation, euphoria, headache, dizziness, acne, photosensitivity, erythema exsudativum multiforme, Stevens Johnson syndrome.
ContraindicationThis section has been translated automatically.
Do not use simultaneously with pimozide, terfenadine, astemizole or cisapride. Do not use in children (insufficient data available).
PreparationsThis section has been translated automatically.
Emend
LiteratureThis section has been translated automatically.
- Fostini AC et al (2013) Prurigo nodularis: an update on etiopathogenesis and therapy. J Dermatologist Treat 24:458-462